Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis (CAMEO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02061540
Recruitment Status : Completed
First Posted : February 13, 2014
Results First Posted : April 12, 2017
Last Update Posted : March 29, 2019
Sponsor:
Information provided by (Responsible Party):
Mirum Pharmaceuticals, Inc.

Tracking Information
First Submitted Date  ICMJE February 11, 2014
First Posted Date  ICMJE February 13, 2014
Results First Submitted Date  ICMJE December 21, 2016
Results First Posted Date  ICMJE April 12, 2017
Last Update Posted Date March 29, 2019
Study Start Date  ICMJE March 2014
Actual Primary Completion Date February 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 27, 2017)
  • Number of Participants With Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: From start of study drug administration until Week 18 ]
    An Adverse Event (AE) was defined as any unfavorable and unintended sign (including a clinically significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE was considered to be related to the investigational drug product. TEAEs were AEs with a start date on or after the first dose of investigational product and started prior to the last dose of investigational product plus 14 days.
  • Change From Baseline in Fasting Serum Bile Acid Level at Week 14 [ Time Frame: Baseline, Week 14 ]
    Serum bile acid levels were evaluated using blood samples collected.
Original Primary Outcome Measures  ICMJE
 (submitted: February 11, 2014)
Safety and tolerability [ Time Frame: 14 weeks ]
Adverse events, changes in vital signs, laboratory and other safety parameters from baseline to week 14
Change History Complete list of historical versions of study NCT02061540 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: February 27, 2017)
  • Change From Baseline in Liver Enzyme Levels in Serum [ Time Frame: Baseline, Week 14 ]
    Levels of liver enzymes such as Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) in serum were evaluated.
  • Change From Baseline in Bilirubin Levels at Week 14 [ Time Frame: Baseline, Week 14 ]
    Total Bilirubin and Direct (Conjugated) Bilirubin levels were evaluated.
  • Change From Baseline in Pruritus as Measured by Adult Itch Reported Outcome (ItchRO) Weekly Sum Score [ Time Frame: Baseline, Week 14 ]
    The Adult ItchRO instrument was completed twice daily using an electronic diary (eDiary). Each morning and evening score had a range from 0-10, with the higher score indicating increasing itch severity. The following was used for assessing the Adult ItchRO daily score: The score which represented the most severe itching for the day (morning or evening) was taken for each day as the daily score (maximum daily score of 10); If only 1 of the 2 scores was available for the day, the score that was available was used as the daily score; If both the morning and the evening scores were missing, the score was considered missing for the day.
Original Secondary Outcome Measures  ICMJE
 (submitted: February 11, 2014)
Efficacy [ Time Frame: 14 weeks ]
Changes in serum bile acids, pruritus, and other biochemical markers of cholestasis and liver disease from baseline to week 14
Current Other Pre-specified Outcome Measures
 (submitted: February 27, 2017)
Change From Baseline for Other Biochemical Markers of Cholestasis: Total Cholesterol, Low Density Lipoprotein Cholesterol [ Time Frame: Baseline, Week 14 ]
Total cholesterol (TC) level and low density lipoprotein cholesterol (LDLC) level were considered as biochemical markers of cholestasis.
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis
Official Title  ICMJE A Pilot, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Sclerosing Cholangitis
Brief Summary The study is an open-label study in adults with primary sclerosing cholangitis to evaluate the safety, tolerability, and effect of 14-weeks of daily dosing of LUM001.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Primary Sclerosing Cholangitis (PSC)
Intervention  ICMJE Drug: LUM001
LUM001 oral dose
Study Arms  ICMJE Experimental: LUM001
LUM001 administered orally once each day
Intervention: Drug: LUM001
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 27, 2017)
27
Original Estimated Enrollment  ICMJE
 (submitted: February 11, 2014)
20
Actual Study Completion Date  ICMJE February 2016
Actual Primary Completion Date February 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Male or female subjects between the ages of 18-80 years, inclusive.
  2. Diagnosis of PSC
  3. If inflammatory bowel disease (IBD) is present, disease activity ≤ 2 (normal to moderate), using the physician assessment on the Mayo ulcerative colitis (UC) disease activity score.
  4. Patients receiving azathioprine for intestinal bowel disease are eligible to participate in the study provided that they have had no IBD exacerbations for at least 6 months.
  5. Females of childbearing potential must have a negative serum pregnancy test [β human chorionic gonadotropin (β-hCG)] during screening and negative urine pregnancy test at the baseline/Day 0 visit.
  6. Sexually active females must be postmenopausal, surgically sterile, or if premenopausal, be prepared to use an effective method (≤ 1% failure rate) of contraception during the trial.
  7. Ability to read and understand English in order to use the study-related questionnaires and the text on the eDiary screen.
  8. Must be willing and able to use an eDiary daily for a minimum of 20 weeks.
  9. Must digitally accept the licensing agreement in the eDiary software at the outset of the study.
  10. Must complete at least 10 eDiary Adult ItchRO reports (AM or PM) during each of two consecutive weeks of the screening period prior to allocation to treatment (maximum possible reports = 14 per week).
  11. Access to phone for scheduled calls from study site.
  12. Must agree to comply with the study protocol procedures and provide written informed consent.

Exclusion Criteria:

  1. Small duct PSC (clinical biochemical and histological features compatible with PSC, but having a normal cholangiogram).
  2. Presence of a dominant stricture unless brushings and/or biopsies of the stricture are negative for dysplasia or malignancy within 6 months of screening.
  3. Surgical or endoscopic biliary tree interventions for treatment of clinically significant strictures within 6 months of screening.
  4. IBD flare (Mayo UC disease activity score > 5 including endoscopic evaluation) within 3 months prior to screening.
  5. Secondary cause of sclerosing cholangitis (e.g., choledocholithiasis, post-surgical biliary stricture, intra-arterial chemotherapy, recurrent pancreatitis, IgG4 associated cholangiopathy, AIDS cholangiopathy).
  6. AST or ALT ≥ 5 x ULN at screening.
  7. History or presence of any other concomitant significant liver disease as assessed by the Investigator.
  8. Medical conditions that may cause nonhepatic increases in ALP (e.g., Paget's disease).
  9. Known history of human immunodeficiency virus (HIV) infection.
  10. The anticipated need for a surgical procedure within 20 weeks from randomization.
  11. Any female who is pregnant or lactating or who is planning to become pregnant within 20 weeks of randomization.
  12. History of cancer, except for basal or squamous cell carcinoma of the skin, or with any laboratory or physical exam or diagnostic procedure finding suggestive of current malignancy.
  13. Family history of any documented hereditary cancer syndrome.
  14. History of alcohol or other substance abuse within 1 year prior to screening.
  15. Receipt of an investigational drug, biologic, or medical device within 30 days prior to Screening, or 5 half-lives of the study agent, whichever is longer.
  16. History of noncompliance with medical regimens, unreliability, mental instability or incompetence that could compromise the validity of informed consent or lead to noncompliance with the study protocol.
  17. Any other conditions or abnormalities which, in the opinion of the Investigator or Medical Monitor, may compromise the safety of the subject, or interfere with the subject participating in or completing the study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02061540
Other Study ID Numbers  ICMJE LUM001-401
2014-005558-21 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Mirum Pharmaceuticals, Inc.
Study Sponsor  ICMJE Mirum Pharmaceuticals, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Study Director Mirum
PRS Account Mirum Pharmaceuticals, Inc.
Verification Date March 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP